Comparison of the 1057 tumors showed KDM5B was most frequently altered in neuroendocrine tumors (28.07%), followed by metastatic prostate adenocarcinoma (8.56%) and TCGA PRAD cohort (0.4%), with the majority of alterations consisting of gene amplification (Figure 1A). Here, KDM5B is linked to neuroendocrine neoplasm.